Save time and money with
Med Tech Market Research


MedTech Business intelligence
supplied through Trade Tracker, Research and Markets and GlobalData

Top Ten Global In-Vitro Diagnostics Companies

Positioning, performance and SWOT analyses

Publication Date: March 2009
Publisher: Business Insights
Pages: 160

Price:
£2,025.00
approximately: $3,086 | €2,290

Buy now >>
(managed by Piribo)

The in-vitro diagnostics (IVD) market continues to grow at a steady pace, driven by new fields such as molecular diagnostics and a growing consumer awareness surrounding disease management. There is also an increasing focus on emerging markets, where healthcare infrastructures are improving. The industry is highly competitive and continues to witness large scale consolidation. Major in-vivo players are beginning to enter the in-vitro market and the regulatory environment is becoming even more stringent, increasing the time to approval for new products.

'The Top 10 Global In-Vitro Diagnostics Companies' explores the global competitive landscape of the IVD industry. This report analyses the size and structure of the market and identifies the latest developments in service offerings, new technologies, strategic approaches and competitive dynamics amongst leading companies. This report assesses the opportunities and threats facing the top 10 IVD companies in the future, and examines their current structure, financial performance, growth strategies and R&D activity. Growth forecasts for key products and regions are also provided.

Key Findings

The global in-vitro diagnostics (IVD) market is forecast to grow at a rate of 6% to reach $50.0bn in 2012. The market has been growing at a rate of 5-6% in recent years, reaching a value of $36.5bn in 2007.

Roche is the largest player in the market with a share of 20%. It is followed by Siemens and Abbott, who both hold 12% of the market. The IVD market is highly consolidated, with the top ten players holding close to 80% market share.

Molecular diagnostics, diabetes care, and emerging markets are the key growth drivers of the IVD industry. Theranostics is an emerging field with great promise and a number of players are making extensive efforts in the area.

Abbott's IVD revenues increased by 10.8% to reach $4.4bn in 2007. However, Abbott's diagnostics margins have been falling and it has recently announced a cost-cutting plan to improve the operating margin of its diagnostics unit. Abbott has also been faced with regulatory issues, with its diagnostics business coming under FDA supervision.

A number of large in-vivo players have entered the IVD market recently, signalling the convergence of the two diagnostic fields. Siemens Healthcare is a prominent example of this trend, following their acquisition of DPC, Bayer Diagnostics and Dade Behring.

Use this report to...

  • Compare the performances of the top 10 IVD companies across key business segments and geographies with this report's analysis of Roche Diagnostics, Siemens Healthcare, Abbott, J&J, Beckman Coulter, Becton Dickinson, bioMerieux, Bayer Diabetes, Sysmex and Bio-Rad.
  • Understand the market dynamics shaping the global IVD industry, forecast key growth areas by product/region and identify deal-making patterns across clinical trials phases and key therapeutic areas.
  • Evaluate the future prospects of major IVD players with this report's examination of R&D expenditure, M&A activity, growth strategies and SWOT analyses for each of the top 10 companies
  • Measure the progress of other leading IVD companies by analysing the financial performances of Inverness, Chiron (Novartis), Olympus, Gen Probe, Hologic/Cytyc, Qiagen, Arkray, DiaSorin, Radiometer, Werfen.

Explore issues including...

Industry consolidation. The IVD market is consolidating further due to a large number of smaller companies striving to increase their market share through M&A activity. Big Pharma is also entering the IVD market through acquisitions.

Growth of molecular diagnostics. Molecular diagnostics is one of the fastest growing segments of the IVD market and is expected to grow at a CAGR of 14% over the next five years.

Stringent regulatory environment. Regulation within the IVD market is becoming increasingly stringent, particularly in the US where the FDA is intensifying its scrutiny on diagnostics companies.

Emergence of theranostics. Advances in the field of genomics are leading to the emergence of theranostics and personalized healthcare. Theranostics uses diagnostic testing to tailor disease treatment to individual needs through the application of molecular diagnostics. A number of players are currently conducting R&D and launching new products in the fields of theranostics and personalized healthcare.

Discover...

  • What are the key trends and issues within the global IVD industry?
  • Who are the top 10 companies in the IVD market?
  • How do the leading companies compare in terms of financial performance, R&D capabilities and coverage by country and category?
  • Who are the leading companies outside of the top 10?
  • Which regions and segments offer the greatest growth opportunities for leading companies?
  • What are the key strategies of the leading IVD companies and how do these strategies drive revenue and market share?
  • What is the future outlook of the global IVD industry?

Buy now >>

Contents

  • The Top Ten Global In-Vitro Diagnostics Companies
    • Executive summary
    • Market Development
    • Roche Diagnostics
    • Siemens Healthcare
    • Abbott
    • J&J
    • Beckman Coulter
    • Becton Dickinson
    • bioMerieux
    • Bayer Diabetes
    • Sysmex
    • Bio Rad
  • Chapter 1 Introduction
    • What is this report about?
    • Methodology and definitions
  • Chapter 2 Market development
    • Summary
    • Overview
    • Market size and growth
    • Growth drivers
    • Key trends in the market
    • Industry consolidation
    • Convergence of IVD and In-vivo
    • Customer consolidation
    • Emergence of theranostics
    • Positioning and performance of top ten players
  • Chapter 3 Roche Diagnostics
    • Summary
    • Company overview
    • Group structure
    • Professional Diagnostics
    • Diabetes Care
    • Molecular Diagnostics
    • Applied Science
    • Recent financial performance
    • Performance by business segments (IVD)
    • Professional Diagnostics
    • Diabetes Care
    • Molecular Diagnostics
    • Performance by geographies
    • Acquisitions and divestments
    • Research and Development
    • Growth strategies
    • SWOT analysis
    • Strengths
    • Dominant market position
    • Diversified portfolio
    • Strong R&D facilities
    • Weaknesses
    • Slow growth of molecular diagnostics business
    • Opportunities
    • Molecular diagnostics market
    • Diabetes care and tissue diagnostics
    • Threats
    • Competition
    • Customer consolidation
    • Stringent regulations
  • Chapter 4 Siemens Healthcare
    • Summary
    • Company overview
    • Group structure
    • Recent financial performance
    • Acquisitions and divestments
    • Research and development
    • Growth strategies
    • SWOT analysis
    • Strengths
    • Full suite of diagnostics offering
    • Strong market position
    • Strong brand name
    • Weaknesses
    • Late entry into IVD
    • Opportunities
    • Integrated offerings
    • Molecular diagnostics market
    • Threats
    • Competition
    • Regulation
  • Chapter 5 Abbott
    • Summary
    • Company overview
    • Group structure
    • Recent financial performance
    • Performance by products
    • Performance by geographies
    • Acquisitions and divestments
    • Research and development
    • Growth strategies
    • SWOT analysis
    • Strengths
    • Diversified revenue stream
    • Strong performance of international diagnostics business
    • Weaknesses
    • Declining margins
    • Regulatory issues
    • Sluggish top line growth in the domestic market
    • Opportunities
    • Molecular diagnostics
    • Diabetes care market
    • Threats
    • Competition
    • Regulatory environment
  • Chapter 6 Johnson & Johnson
    • Summary
    • Company overview
    • Group structure
    • Ortho-Clinical Diagnostics
    • Veridex
    • LifeScan
    • Recent financial performance
    • Performance by businesses
    • LifeScan
    • Ortho-Clinical Diagnostics
    • Veridex
    • Acquisitions and divestments
    • Growth strategies
    • Strategic partnerships
    • Acquisitions
    • SWOT analysis
    • Strengths
    • Strong market position
    • J&J brand
    • Strong topline growth
    • Weaknesses
    • Small contribution to J&J revenues
    • Opportunities
    • Amic acquisition
    • Diabetes monitoring market
    • Threats
    • Competition
    • Regulations
  • Chapter 7 Beckman Coulter (Beckman)
    • Summary
    • Company overview
    • Group structure
    • Clinical Diagnostics
    • Recent financial performance
    • Performance by geographies
    • Acquisitions and divestments
    • Research and Development
    • Growth strategies
    • Focus on immunoassay systems and molecular diagnostics
    • Expansion into emerging markets
    • SWOT analysis
    • Strengths
    • Global presence
    • Strong market position
    • Diverse product portfolio
    • Strong performance of immunoassay systems
    • Weaknesses
    • Late entry into molecular diagnostics
    • Lower operating margin
    • Opportunities
    • Emerging markets
    • Immunoassay systems
    • Threats
    • Consolidation of customers
    • Stiff competition
  • Chapter 8 Becton Dickinson (BD)
    • Summary
    • Company overview
    • Group structure
    • Preanalytical Systems
    • Diagnostic Systems
    • Recent financial performance
    • Performance by business segments
    • Preanalytical Systems
    • Diagnostics Systems
    • Acquisitions and divestments
    • Research and Development
    • Growth strategies
    • Strategic acquisitions
    • Organic growth measures
    • SWOT analysis
    • Strengths
    • Increased focus on Research and Development
    • Acquisition of TriPath and GeneOhm
    • Global presence
    • Weaknesses
    • Falling margins
    • Weak BGM business
    • Opportunities
    • HAI market
    • Cancer diagnostics market
    • Threats
    • Competition
    • Regulations
  • Chapter 9 bioMerieux
    • Summary
    • Company overview
    • Group structure
    • Clinical Diagnostics
    • Industrial Diagnostics
    • Recent financial performance
    • Performance by geographies
    • Acquisitions and divestments
    • Research and Development
    • Growth strategies
    • Geographic expansion
    • Infectious diseases and high-medical value tests
    • SWOT analysis
    • Strengths
    • Global presence
    • Strong R&D capabilities
    • Strong market position
    • Weaknesses
    • Weak performance of Immunoassay
    • Divestments
    • Opportunities
    • Emerging markets
    • Molecular Biology market
    • Threats
    • Competitive and pricing pressures
    • Regulatory environment
  • Chapter 10 Bayer Healthcare
    • Summary
    • Company overview
    • Group structure
    • Recent financial performance
    • Acquisitions and divestments
    • Growth strategies
    • SWOT analysis
    • Strengths
    • Strong revenue growth
    • Strong position in diabetes care market
    • Weaknesses
    • Divestment of clinical diagnostics business
    • Small size of diabetes care business within Bayer
    • Opportunities
    • Strategic acquisition and partnerships
    • Threats
    • Loss of market share
  • Chapter 11 Sysmex
    • Summary
    • Company overview
    • Group structure
    • Recent financial performance
    • Performance by product segments
    • Performance by geographies
    • Japan
    • Americas
    • Europe
    • China
    • Asia-Pacific
    • Acquisitions and divestments
    • Research and Development
    • Growth strategies
    • Strategic alliances
    • Strengthening global sales and distribution network
    • Focus on Asia
    • Expansion into life sciences
    • SWOT analysis
    • Strengths
    • Strong topline growth
    • Strong growth in profits
    • Diverse geographic portfolio
    • Weaknesses
    • Weak performance in key markets
    • Dependence on Hematology business
    • Opportunities
    • Strategic partnerships
    • Emerging markets
    • Threats
    • Weak Japanese market
    • Stiff competition
  • Chapter 12 Bio Rad
    • Summary
    • Company overview
    • Group structure
    • Recent financial performance
    • Performance by geographies
    • Acquisitions and divestments
    • Research and Development
    • Growth strategies
    • Strategic acquisitions
    • New products
    • SWOT analysis
    • Strengths
    • Diversified revenues
    • Strong R&D focus
    • Strong revenue growth
    • Weaknesses
    • Limited product portfolio
    • Sluggish growth in Japan
    • Opportunities
    • DiaMed's acquisition
    • New products
    • Threats
    • Intense competition
    • Regulations
  • Chapter 13 Other leading players
    • Inverness
    • Company description
    • Recent financial performance
    • Chiron (Novartis Vaccines and Diagnostics)
    • Company description
    • Recent financial performance
    • Olympus
    • Company description
    • Recent financial performance
    • Gen Probe
    • Company description
    • Recent financial performance
    • Hologic / Cytyc
    • Company description
    • Recent financial performance
    • Qiagen
    • Company description
    • Recent financial performance
    • Arkray
    • Company description
    • DiaSorin
    • Company description
    • Recent financial performance
    • Radiometer
    • Company description
    • Recent financial performance
    • Werfen
    • Company description
    • Recent financial performance
    • Other major players
    • Index
  • List of Figures
    • Figure 2.1: Global IVD market size and growth, 2007-2012
    • Figure 2.2: Market share of Top 10 IVD companies, 2007
    • Figure 2.3: Market positioning of top 10 IVD companies, 2007*
    • Figure 2.4: Comparative Analysis of top 10 IVD companies
    • Figure 3.5: Roche Diagnostics' financial performance ($m), 2003-2007
    • Figure 3.6: Roche Diagnostics' revenue break-up by geography (%), 2007
    • Figure 3.7: Roche SWOT analysis
    • Figure 4.8: Siemens Healthcare SWOT analysis
    • Figure 5.9: Abbott's IVD financial performance ($m), 2003-2007*
    • Figure 5.10: Abbott's IVD revenue break-up by geography (%), 2007
    • Figure 5.11: Abbott SWOT analysis
    • Figure 6.12: J&J's IVD financial performance ($m), 2003-2007
    • Figure 6.13: J&J (IVD business) SWOT analysis
    • Figure 7.14: Beckman's IVD financial performance ($m), 2005-2007*
    • Figure 7.15: Beckman's revenue break-up by geography (%), 2007*
    • Figure 7.16: Beckman SWOT analysis
    • Figure 8.17: BD Diagnostics' financial performance ($m), 2005-2007*
    • Figure 8.18: BD SWOT analysis
    • Figure 9.19: bioMerieux's financial performance ($m), 2003-2007*
    • Figure 9.20: bioMerieux's revenue break-up by geography (%), 2007
    • Figure 9.21: bioMerieux SWOT analysis
    • Figure 10.22: Bayer Diabetes Care's financial performance ($m), 2003-2007*
    • Figure 10.23: Bayer Healthcare SWOT analysis
    • Figure 11.24: Sysmex Diagnostics' financial performance ($m), 2003-2007
    • Figure 11.25: Sysmex's revenue break-up by geography (%), 2007
    • Figure 11.26: Sysmex SWOT analysis
    • Figure 12.27: Bio Rad Clinical Diagnostics' financial performance ($m), 2003-2007
    • Figure 12.28: Bio Rad's revenue break-up by geography (%), 2007*
    • Figure 12.29: Bio Rad SWOT analysis
    • Table 2.1: Top ten companies' revenue, profitability & growth (2003-2007)
    • Table 3.2: Roche Diagnostics snapshot
    • Table 3.3: Roche Diagnostics' financial performance ($m), 2003-2007
    • Table 3.4: Roche Diagnostics' IVD business segments performance ($m),
    • Table 3.5: Roche Diagnostics performance by geography ($m), 2007*
    • Table 3.6: Roche Diagnostics' R&D expenditure, 2006-2007
    • Table 4.7: Siemens Healthcare snapshot
    • Table 4.8: Siemens Healthcare Diagnostics' product segments performance ($m), 2007
    • Table 4.9: Siemens Healthcare Diagnostics' geographic performance ($m),
    • Table 5.10: Abbott snapshot
    • Table 5.11: Abbott's IVD financial performance ($m), 2003-2007
    • Table 5.12: Abbott' IVD product segments performance ($m),
    • Table 5.13: Abbott's IVD performance by geography ($m), 2005-2007
    • Table 6.14: J&J snapshot
    • Table 6.15: J&J's IVD financial performance ($m), 2003-2007
    • Table 6.16: J&J's IVD businesses performance ($m), 2005-2007
    • Table 7.17: Beckman snapshot
    • Table 7.18: Beckman's IVD financial performance ($m), 2005-2007
    • Table 7.19: Beckman's performance by geography ($m), 2005-2007
    • Table 7.20: Beckman's R&D expenditure, 2005-2007
    • Table 8.21: BD snapshot
    • Table 8.22: BD Diagnostics' financial performance ($m), 2005-2007
    • Table 8.23: BD Diagnostics' business segments performance ($m),
    • Table 8.24: BD Diagnostics' R&D expenditure, 2006-2007
    • Table 9.25: bioMerieux snapshot
    • Table 9.26: bioMerieux's financial performance ($m), 2003-2007
    • Table 9.27: bioMerieux's R&D expenditure, 2005-2007
    • Table 10.28: Bayer Healthcare snapshot
    • Table 10.29: Bayer Diabetes Care's financial performance ($m), 2003-2007
    • Table 11.30: Sysmex snapshot
    • Table 11.31: Sysmex Diagnostics' financial performance ($m), 2003-2007
    • Table 11.32: Sysmex Diagnostics' product segments performance ($m),
    • Table 11.33: Sysmex's performance by geography ($m), 2005-2007
    • Table 11.34: Sysmex's R&D expenditure, 2005-2007
    • Table 12.35: Bio Rad snapshot
    • Table 12.36: Bio Rad Clinical Diagnostics' financial performance ($m), 2003-2007
    • Table 12.37: Bio Rad's performance by geography ($m), 2005-2007
    • Table 12.38: Bio Rad's R&D expenditure, 2005-2007
    • Table 12.39: Inverness snapshot
    • Table 12.40: Inverness's IVD financial performance ($m), 2003-2007
    • Table 12.41: Chiron snapshot
    • Table 12.42: Novartis Vaccines and Diagnostics' financial performance ($m), 2006-2007*
    • Table 12.43: Olympus snapshot
    • Table 12.44: Olympus' IVD financial performance ($m), 2003-2007
    • Table 12.45: Gen Probe snapshot
    • Table 12.46: Gen Probe's financial performance ($m), 2003-2007
    • Table 12.47: Hologic snapshot
    • Table 12.48: Hologic Diagnostics' financial performance ($m), 9months 2008
    • Table 12.49: Qiagen snapshot
    • Table 12.50: Qiagen's financial performance ($m), 2003-2007*
    • Table 12.51: Arkray snapshot
    • Table 12.52: DiaSorin snapshot
    • Table 12.53: DiaSorin's financial performance ($m), 2003-2007
    • Table 12.54: Radiometer snapshot
    • Table 12.55: Danaher Medical Technologies' financial performance ($m), 2005-2007*
    • Table 12.56: Werfen snapshot
    • Table 12.57: Werfen's financial performance ($m), 2003-2007*
    • Table 12.58: Other major players

Buy now >>

 

To top